Finoriq research workspace
Actinium Pharmaceuticals, Inc. (ATNM) Historical Metrics
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted. Review ATNM fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
- Company
- Actinium Pharmaceuticals, Inc. (ATNM)
- Ticker
- ATNM
- Market Cap
- $27.7M
- Latest Price
- $0.883
- Industry
- Biotech & Pharma
Actinium Pharmaceuticals, Inc. (ATNM) Current Valuation Metrics
Static valuation preview for Actinium Pharmaceuticals, Inc. (ATNM). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 335x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -77.9% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -75.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 13.1x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.